Therefore, investigation of the effects of GSK3β inhibition on primary CRC cells (e.g. primary cultures of tumors from CRC patients and patient-derived tumor xenografts) will facilitate therapeutic application in CRC patients. This evidence concerns the gene GSK3B and colorectal carcinoma.